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BACKGROUND: It is unknown whether breast cancer (BC) characteristics among young women treated with radiotherapy (RT)
for Hodgkin’s lymphoma (HL) differ from sporadic BC.
METHODS: Using population-based data, we calculated BC risk following HL according to clinicopathologic features.
RESULTS: Compared with BC in the general population, risks of oestrogen receptor (ER)-positive/progesterone receptor (PR)-positive
and ER-negative/PR-negative BC in young, irradiated HL survivors were increased five-fold (95% confidence interval (CI)¼3.81–6.35)
and nine-fold (95% CI¼6.93–12.25), respectively. Among 15-year survivors, relative risk of ER-negative/PR-negative BC exceeded by
two-fold (P¼0.002) than that of ER-positive/PR-positive BC.
CONCLUSION: Radiotherapy may disproportionately contribute to the development of BC with adverse prognostic features among
young HL survivors.
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Young women treated with radiotherapy (RT) for Hodgkin’s
lymphoma (HL) have an elevated risk of developing breast cancer
(BC) compared with the general population (Dores et al, 2002;
Hodgson et al, 2007). Hospital-based, case–control studies have
addressed whether features of radiation-related BC differ from
primary BC (Yahalom et al, 1992; Gaffney et al, 2001; Janov et al,
2001; Castiglioni et al, 2007; Sanna et al, 2007). As the largest
report included fewer than 60 HL cases (Castiglioni et al, 2007),
and only one focused on females diagnosed with HL at age 40 years
or younger (Janov et al, 2001), statistical power to evaluate risk of
BC characteristics compared with sporadic BC may have been
limited in these studies. To date, no population-based series of
young HL survivors has assessed BC risk according to clinico-
pathologic characteristics. Therefore, we sought to assess risk of
BC subtypes among long-term survivors of HL treated with RT
compared with BC in the general population.
MATERIALS AND METHODS
We evaluated the risk of invasive BC among female 5-year
survivors of HL diagnosed before 35 years of age who received
RT as part of initial therapy for HL and who were reported to
one of nine cancer registry areas of the Surveillance, Epidemiology
and End Results (SEER) Programme in the United States during
1973–2000 and followed through 2005 (SEER-9, 2008). The SEER
Programme classifies information on histology and topography
according to the third edition of the International Classification of
Diseases for Oncology (ICD-O-3) (Fritz et al, 2000). Most
clinicopathologic variables were defined as in previous studies
(Anderson et al, 2001, 2002) and are detailed in Table 1. The SEER
Programme began collecting information on tumour size and
regional lymph node (LN) involvement in 1988, and oestrogen
receptor (ER) and progesterone receptor (PR) status in 1990. For
consistency, analyses including data on ER and PR status, tumour
size, grade and LN involvement were limited to BC cases diagnosed
in 1990 or later.
Standardised incidence ratios (SIRs) were calculated as the ratio
of observed (Obs)-to-expected number of second or higher order
invasive BC using methods previously described (Curtis and Ries,
2006). Age-, race- and calendar year-specific incidence rates (IRs)
of invasive BC were computed for each group of BC clinicopatho-
logic characteristics from the general SEER population, as specified
in Table 1. We calculated exact, two-sided, Poisson-based 95%
confidence intervals (CIs). Multivariate analyses using Poisson
regression methods for grouped survival data were conducted
within the cohort to compute relative risks (RRs) of ratios of SIRs,
taking into account age (5-year age groups) at HL diagnosis,
calendar year (5-year calendar periods) of HL diagnosis and time
since HL diagnosis (5-year calendar periods) (Preston et al, 1993).
This approach incorporates SEER primary BC IRs (specific for
clinical and pathologic features) to account for the natural rise in
BC risk with increasing age (Yasui et al, 2003).
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yAge-specific IRs (o15, 15–24, 25–34, 35–44, 45–54, 55–64,
65–74, 75–84 years) for first primary female BC in the general
population diagnosed during 1990–2005 were calculated using the
SEER*Stat Incidence Rate module. BC age-specific IRs were
calculated among HL survivors diagnosed with HL before 35 years
of age and treated with RT by dividing the number of BC cases
diagnosed during 1990–2005 at specified attained ages (o15,
15–24, 25–34, 35–44, 45–54, 55–64, 65–74, 75–84 years) by the
HL population at-risk. There were no cases of BC diagnosed before
15 years of age or at the age of 65 years and older among HL
survivors. All IRs were expressed per 100 person-years and plotted
on a log-linear scale as previously described (Devesa et al, 1995).
IRs based on fewer than 5 cases were omitted from the figures.
RESULTS
Overall, 2645 young female 5-year survivors of HL diagnosed
between 1973–2000 and treated with RT as part of initial therapy
had a six-fold risk of developing invasive BC compared with that
expected in the general population (SIR¼6. 13, 95% CI¼5.23–7.13;
Obs.¼166) (Table 1). Standardised incidence ratios decreased with
increasing attained age; however, compared with those o35 years
at BC diagnosis, statistically significant differences among older
attained age groups were not observed when the RRs were adjusted
for age at HL diagnosis. Most BCs were diagnosed after 1989, and
risks were similar across calendar year periods (PRR40.5). Ductal
adenocarcinoma and upper outer quadrant tumours were diagnosed
most frequently. Relative risks did not differ significantly according
to histology or laterality.
In comparison with that expected for primary BC in the general
population, there were no significant differences in risks for
developing localised, regional or distant stage BC following RT for
HL. Multivariate analyses comparing SIRs (while adjusting for age
at HL diagnosis and time since HL diagnosis) did not demonstrate
statistically significant differences in risk of BC for regional stage
(RR¼0.87) or distant stage (RR¼0.88) disease compared with
localised stage BC. We also considered the possibility that
screening for subsequent radiation-related BC could increase the
likelihood of detecting localised BC in the more recent calendar
years, and therefore assessed differences in RT-related BC risk by
stage over time (1990–1993, 1994–1997, 1998–2001, 2002–2005).
There was no significant trend observed for localised (PTrend¼0.7),
regional (PTrend¼0.6), distant (PTrend¼1.0) or unknown (PTrend¼0.9)
stages according to calendar year groups. Among LN-negative BC
diagnosed during 1990–2005, we observed somewhat lower risks for
larger (42cm) than smaller (p2cm) tumours; however, this difference
was not statistically significant in multivariate RR analyses (PRR¼0.12).
Irradiated HL survivors had a greater than nine-fold risk of
developing ER-negative/PR-negative BC during 1990–2005 as
compared with a nearly five-fold risk of ER-positive/PR-positive
tumours. In age- and time-adjusted multivariate analyses, the
RR of ER-negative/PR-negative disease was 66% higher than
ER-positive/PR-positive BC (PRR¼0.008). The risk of developing
high-grade BC was modestly elevated, but did not differ signifi-
cantly from risk of low-grade tumours (RR¼1.26, PRR¼0.19).
To assess for a possible radiation effect, we further evaluated
hormone receptor status and grade according to time since HL
diagnosis. The SIR of ER-negative/PR-negative BC and high-grade
BC showed greater increases with time since HL diagnosis than did
ER-positive/PR-positive or low-grade BC, respectively (Table 2).
Among 15-year HL survivors, risk of receptor-negative BC
was two-fold higher than receptor-positive disease (RR¼1.99,
PRR¼0.002). Fifteen-year survivors also had a 52% significantly
greater risk of high-grade compared with low-grade tumours
(RR¼1.52, PRR¼0.03).
Age-specific BC IRs among HL survivors and primary BC IRs in
the general SEER population are depicted in Figure 1. In contrast
Table 1 Risk of invasive breast cancer among 2645 female 5-year
survivors (32731 person-years) of Hodgkin’s lymphoma diagnosed before
age 35 years, initially treated with radiotherapy, and reported to the SEER-9
Programme, 1973–2005
BC characteristics Obs. SIR (95% CI) RR
a (95% CI) PRR
Total 166 6.13 (5.23–7.13) NA NA NA
Attained age (years)
o35 33 15.54 (10.70–21.83) 1.00 NA
35–44 82 6.68 (5.31–8.29) 0.70 (0.47–1.08) 0.10
X45 51 4.02 (2.99–5.28) 0.66 (0.40–1.09) 0.10
Attained calendar year
1978–1989 11 4.69 (2.34–8.40) 1.00 NA
1990–2005 155 6.26 (5.32–7.33) 1.05 (0.59–2.06) 40.5
Histology
b
Ductal adenocarcinoma 131 6.45 (5.39–7.65) 1.00 NA
Lobular carcinoma 9 5.47 (2.50–10.39) 1.00 (0.47–1.86) 40.5
Medullary carcinoma 7 15.49 (6.23–31.92) 2.17 (0.91–4.32) 0.08
Other or not specified 19 4.06 (2.44–6.34) 0.65 (0.39–1.03) 0.07
Site
c
Upper outer quadrant 82 8.30 (6.60–10.31) 1.00 NA
Lower outer quadrant 10 5.78 (2.77–10.63) 0.70 (0.34–1.28) 0.26
Upper inner quadrant 5 1.96 (0.64–4.56) 0.24 (0.08–0.53) o0.001
Lower inner quadrant 8 6.32 (2.73–12.46) 0.79 (0.35–1.54) 40.5
Central/nipple 8 5.43 (2.34–10.70) 0.68 (0.30–1.31) 0.27
Overlapping 30 5.50 (3.71–7.86) 0.66 (0.43–1.00) 0.048
Not specified 23 4.85 (3.07–7.27) 0.58 (0.36–0.91) 0.02
Laterality
Right 84 6.28 (5.01–7.77) 1.00 NA
Left 82 6.04 (4.81–7.50) 0.96 (0.71–1.31) 40.5
Stage
Localised 97 6.31 (5.12–7.70) 1.00 NA
Regional 58 5.89 (4.47–7.61) 0.87 (0.62–1.20) 0.39
Distant 8 5.84 (2.52–11.50) 0.88 (0.39–1.70) 40.5
Not specified 3 6.07 (1.25–17.74) 0.84 (0.21–2.24) 40.5
Limited to breast cancer cases diagnosed 1990–2005
d
Tumour size and LN
e
p2cm and
LN negative
63 6.40 (4.92–8.19) 1.00 NA
42cm and
LN negative
16 4.62 (2.64–7.51) 0.66 (0.37–1.11) 0.12
p2cm and
LN positive
24 6.62 (4.24–9.85) 0.96 (0.59–1.52) 40.50
42cm and
LN positive
25 5.50 (3.56–8.12) 0.76 (0.47–1.20) 0.24
Grade
f
Low 57 5.02 (3.80–6.51) 1.00 NA
High 75 7.33 (5.77–9.19) 1.26 (0.89–1.80) 0.19
Not specified 23 7.25 (4.60–10.89) 1.34 (0.81–2.16) 0.25
ER/PR
Positive/positive 63 4.96 (3.81–6.35) 1.00 NA
Positive/negative 12 6.23 (3.22–10.88) 1.24 (0.64–2.22) 40.50
Negative/positive 1 1.31 (0.03–7.30) 0.24 (0.01–1.10) 0.07
Negative/negative 51 9.31 (6.93–12.25) 1.66 (1.14–2.41) 0.008
Other and
unspecified
g
28 7.21 (4.79–10.43) 1.38 (0.87–2.13) 0.17
Abbreviations: BC¼breast cancer; CI¼confidence interval (exact); ER¼oestrogen
receptor; HL¼Hodgkin’s lymphoma; LN¼lymph nodes; NA¼not applicable;
Obs¼observed number of breast cancers; PR¼progesterone receptor; RR¼
relative risk; SEER¼Surveillance, Epidemiology and End Results; SIR¼standardised
incidence ratio.
aAttained calendar year and attained age are adjusted for age at HL
diagnosis. All other analyses are adjusted for age at HL and time since HL diagnosis.
bDuctal adenocarcinoma includes International Classification of Diseases for Oncology,
third edition (ICD-O-3) morphology codes M8500 and M8501, lobular carcinoma
includes M8520 and M8521, and medullary carcinoma includes M8510–8512.
cICD-O-
3 topography codes include upper outer quadrant (C504, C506), lower outer quadrant
(C505), upper inner quadrant (C502), lower inner quadrant (C503), central/nipple
(C500–501), overlapping (C508), and not specified (C509).
dIncludes 2549 female 5-
year survivors of HL initially treated with radiotherapy who developed subsequent
breast cancer (Obs.¼155).
eLimited to localised and regional stage disease. Excludes 27
women with distant or unknown stage (n¼10) and localised or regional stage disease
without known tumour size and/or lymph node involvement (n¼17).
fGrade was
considered in three categories: low (grades I and II), high (grades III and IV) and
unspecified.
gIncludes ‘testing not done’, ‘borderline’ and ‘unknown’ ER and/or PR status.
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PR-negative and ER-positive/PR-positive BC rates in the SEER
population, IRs for receptor-negative BC among HL survivors
approached those of receptor-positive disease as age increased
(Figure 1A). In the general population, high-grade features
predominated until approximately age 40 years, whereas low-
grade BC was more common at older ages (Figure 1B). Among HL
survivors, IRs of high-grade tumours exceeded that of low-grade
tumours until approximately age 50 years.
DISCUSSION
This is the first study to demonstrate that young women treated
with RT for HL have an increased risk of developing ER-positive/
PR-positive and ER-negative/PR-negative BC compared with
expected values in an age-matched series of BC in the general
population. Overall, the RR of ER-negative/PR-negative BC was
66% higher than ER-positive/PR-positive BC among 5-year HL
survivors, and nearly two-fold higher among 15-year survivors.
In addition, 15-year survivors had a significant 50% greater
risk of developing high-grade than low-grade BC compared with
primary BC. Although longer follow-up is needed, temporal
patterns suggest that radiation may contribute disproportionately
to the development of BC with more adverse prognostic features
than would be expected in the general population.
In contrast to our findings, after accounting for patient age,
hospital-based case–control studies of BC among HL survivors
have not found a significant variation in hormone-receptor status
when compared with primary BC controls (Gaffney et al, 2001; Janov
et al, 2001; Castiglioni et al, 2007). However, none of these studies
considered time since HL diagnosis, and all were limited by small
numbers of BC cases. A population-based study in North Carolina
found a higher nonsignificant risk for ER-negative/PR-negative than
ER-positive/PR-positive BC among women with a history of previous
medical radiation to the chest compared with unexposed women,
particularly at pre- and peri-menopausal ages (Huang et al, 2000).
However, the study was based on fewer than 55 exposed cases, and
risk according to time since exposure was not assessed.
Among HL survivors, higher SIRs for ER-negative/PR-negative
BC than ER-positive/PR-positive BC may reflect lower baseline
IRs for ER-negative/PR-negative BC in the general population.
However, in our study, the incidence patterns by BC subtype
among individuals with HL were distinct from those of primary
BC. Whereas incidence of hormone receptor-positive BC in the
general population exceeds that of ER-negative/PR-negative BC
with advancing age, IR patterns by subtype among irradiated HL
survivors revealed no such divergence. It is also important to
consider that young women treated for HL may experience
premature ovarian failure related to HL therapy (Trichopoulos
et al, 1972; Fisher and Cheung, 1984); therefore, hormonal BC risk
factors may differ from those in the general population. Additional
follow-up of our study population will help clarify whether the risk
patterns persist over time as HL survivors age and begin (or continue)
to accumulate follow-up in the post-menopausal years.
Similar to others studies (Yahalom et al, 1992; Gaffney et al,
2001; Janov et al, 2001; Castiglioni et al, 2007; Sanna et al, 2007),
we did not observe significant differences in overall risk of high-
grade and low-grade tumours. However, with increasing time since
HL diagnosis, risk of high-grade BC exceeded that of low-grade BC,
suggesting a radiation effect. Although this observation has not
been reported in other studies of HL survivors compared with
hospital controls, none have considered time since HL diagnosis
(Yahalom et al, 1992; Gaffney et al, 2001; Janov et al, 2001;
Castiglioni et al, 2007; Sanna et al, 2007).
Other studies of HL survivors (Wolden et al, 2000; Castiglioni
et al, 2007) have found that radiation-related BCs have a similar
stage distribution to that of primary BC, which is consistent with
Hormone receptors Grade
R
a
t
e
 
p
e
r
 
1
0
0
 
f
e
m
a
l
e
-
y
e
a
r
s
1
0.1
0.01
0.001
1
0.1
0.01
0.001
40 50 60 70 80 90 20 30 40 50 60 70 80 90 20 30
HL, ER+/PR+
HL, ER–/PR–
SEER, ER+/PR+
SEER, ER–/PR–
HL, low grade
HL, high grade
SEER, low grade
SEER, high grade
Age at diagnosis of breast cancer
Figure 1 Age-specific incidence rates of female breast cancer (1990–2005)
among 5-year survivors of Hodgkin’s lymphoma (HL) diagnosed before
35 years of age and treated with radiotherapy and among the general
population in nine registry areas of the Surveillance, Epidemiology and
End Results (SEER) Programme, (A) according to oestrogen-receptor (ER)
and progesterone-receptor (PR) status and (B) grade.
Table 2 Risk of invasive breast cancer occurring in 1990 or later among 2549 female 5-year survivors of Hodgkin’s lymphoma diagnosed before 35 years
of age and treated with initial radiotherapy diagnosed in the SEER-9 Programme (1973–2005)
Time since Hodgkin lymphoma
5–9 years 10–14 years X15 years Breast
cancer
characteristics Obs. SIR (95% CI) RR
a (95% CI) PRR Obs. SIR (95% CI) RR
a (95% CI) PRR Obs. SIR (95% CI) RR
a (95% CI) PRR
Grade
b
Low 3 3.06 (0.63–8.94) 1.00 NA 0.28 10 4.75 (2.28–8.73) 1.00 NA 40.5 44 5.32 (3.87–7.15) 1.00 NA 0.03
High 2 1.47 (0.18–5.32) 0.37 (0.05–2.30) 13 5.63 (3.00–9.63) 1.07 (0.46–2.53) 60 9.14 (6.98–11.77) 1.52 (1.03–2.26)
ER/PR
Positive/positive 3 2.46 (0.51–7.19) 1.00 NA 0.48 12 4.77 (2.47–8.34) 1.00 NA 0.44 48 5.35 (3.95–7.09) 1.00 NA 0.002
Negative/negative 1 1.32 (0.03–7.37) 0.46 (0.02–3.69) 9 7.21 (3.30–13.69) 1.42 (0.57–3.39) 41 11.81 (8.48–16.02) 1.99 (1.30–3.02)
Abbreviations: BC¼breast cancer; CI¼confidence interval (exact); ER¼oestrogen receptor; NA¼not applicable; Obs.¼observed number of breast cancers;
PR¼progesterone receptor; RR¼relative risk; SEER¼Surveillance, Epidemiology and End Results; SIR¼standardised incidence ratio.
aAdjusted for age at Hodgkin’s
lymphoma diagnosis.
bLow grade includes grades I and II, and high grade includes grades III and IV.
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proportion of early-stage BC among women treated for HL after
1990, perhaps due to increasing use of mammography (Wolden
et al, 2000). However, many long-term HL survivors remain
unaware of their increased risk of BC (Diller et al, 2002), and a
recent survey of childhood cancer survivors treated with RT
reported much lower BC screening rates than recommended
(Oeffinger et al, 2009).
The strengths of our study include the large number of second
BCs occurring among nearly 2700 irradiated HL survivors
diagnosed over a 30-year period. A unique feature is the
population-based study design, which compared BC following
HL to that expected in the general population using age-matched,
subtype-specific BC IRs. Despite decentralised hormone receptor
testing in various laboratories, SEER data have been shown to be
reasonably reliable for ER-positive/PR-positive and ER-negative/
PR-negative BC subtypes (Ma et al, 2009). Limitations include the
lack of detailed information on RT dose, additional HL treatments
and other established BC risk factors.
Our population-based study suggests that long-term survivors of
HL treated with RT before 35 years of age have a significantly
higher risk of developing ER-negative/PR-negative than ER-positive/
PR-positive BC, particularly among 15-year survivors. Fifteen-year
HL survivors also had a significantly higher risk of developing high-
grade than low-grade tumours. Although confirmatory studies are
needed, the temporal patterns we observed suggest that radiation
may contribute disproportionately to the development of BC with
adverse prognostic features.
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